Researchers at ETH Zurich have identified a previously unknown mechanism driving Alzheimer's disease and developed an experimental compound that halted nerve cell death in mice, extended their lifespan, and tackled a biological pathway untouched by existing dementia medications.
The compound, called Compound 10, emerged from nearly two decades of detective work led by Professor Ursula Quitterer in molecular pharmacology. Her team's findings, published in Cell Reports Medicine, pinpoint a regulatory protein called GRK2 as a major culprit in dementia development.
The investigation began when Quitterer received brain tissue samples from a colleague at Ain Shams University Hospital in Cairo, harvested during tumor surgeries from both dementia patients and healthy individuals. Those samples became the cornerstone of a long hunt into GRK2's role in the disease.
GRK2 normally helps cells respond to signals and manage stress, working actively in organs including the heart and brain. But the researchers discovered something alarming: in dementia patients' brains, the protein exists in an inactive form that accumulates in dangerous quantities. The same pattern showed up in mice engineered to develop Alzheimer's-like symptoms.
When inactive GRK2 molecules clump together inside nerve cells, they attach to mitochondria, the cellular powerhouses, and clog their pores. This blocks energy production and triggers cellular distress. Worse, the inactive protein spurs more production of amyloid beta, a fragment long associated with Alzheimer's progression.
The result is a vicious spiral: amyloid beta stresses nerve cells further, which generates more inactive GRK2, which forms larger aggregates, which feeds the disease cycle forward.
Compound 10 breaks that loop. In laboratory and animal testing, the compound blocked harmful GRK2 clumping, restored mitochondrial function, reduced amyloid beta buildup, and slowed nerve cell death. Treated mice also showed unexpected benefits: improved heart function and fewer gray hairs as they aged.
Why did two decades pass before this breakthrough? Quitterer explains the brutal mathematics of dementia research. Alzheimer's targets aging organisms, so researchers work with older mice typically between eighteen months and two years old. Each experiment requires comparable time to yield reliable results. The pace is glacial compared to cancer research, where faster-developing tumors compress timelines.
The team has patented Compound 10 and is now hunting for a partner company to shepherd it toward human trials. Current Alzheimer's drugs merely delay disease progression by months at best, leaving enormous room for improvement. Combining Compound 10 with existing medications could eventually deliver more meaningful results and better patient outcomes.
Much groundwork remains before the compound reaches human testing, but Quitterer's team has handed the field a new target and a fresh mechanism to attack. In a disease as complex and resistant as Alzheimer's, that represents genuine progress.
Author Jessica Williams: "Two decades to find one broken protein and a possible fix sounds long, but in Alzheimer's research, that's practically overnight."
Comments